
## Child and Adolescent Immunization Schedule



For access to Notes, Appendix, and Addendum, visit: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-indications.html#addendum-child

Table

Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

en hare hv the who fall hehind Eor th follow: 4

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).	<b>ad with th</b> een doses,	e notes tha see the cat	<b>it follow.</b> F ch-up sche	or those w edule (Table	ho fall behind c e 2).	or start late	e, provide catch-ı	up vaccinatio	n at the earliest	opportunity	as indicated b	oy the green	. bars.
Vaccine and other immunizing agents	Birth	1 mo	2 mos	4 mos	6 mos 9 mos	_	12 mos 15 mos	18 mos 19–23 mos	23 mos 2–3 yrs	4-6 yrs	7–10 yrs   11–12 yrs   13–15 yrs	12 yrs 13–15	5 yrs 16 yrs 17–18 yrs
Respiratory syncytial virus (RSV-mAb [Nirsevimab])		1 dose depending on RSV vaccination status,	ending on m on status, S	, See Notes	1 dc	ose (8 throu	dose (8 through 19 months), See Notes	e Notes					
Hepatitis B (HepB)	1 <sup>st</sup> dose		ose		•	3rd dose	lose	Î					
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See Notes								
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose		<ul> <li>4<sup>th</sup> dose</li> </ul>	se		5 <sup>th</sup> dose			
Haemophilus influenzae type b (Hib)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See Notes	ēų	<ul> <li><sup>3<sup>rd</sup> or 4<sup>th</sup> dose, See Notes</sup></li> </ul>						
Pneumococcal conjugate (PCV15, PCV20)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	¥	4 <sup>th</sup> dose						
Inactivated poliovirus (IPV <18 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	•	3 <sup>rd</sup> d	3 <sup>rd</sup> dose	1		4 <sup>th</sup> dose			See Notes
COVID-19 (1vCOV-mRNA, 1vCOV-aPS)							1 or mo	ore doses of up	1 or more doses of updated (2023–2024 Formula) vaccine (See Notes)	Formula) vac	cine (See Notes	(1	
							Annual vacci	Annual vaccination 1 or 2 doses	oses			Annual vacc	Annual vaccination 1 dose only
Influenza (LAIV4)									Anr	Annual vaccination 1 or 2 doses	5	Annual vace	Annual vaccination 1 dose only
Measles, mumps, rubella (MMR)					See Notes	¥	1 <sup>st</sup> dose			2 <sup>nd</sup> dose			
Varicella (VAR)						¥	4 1 <sup>st</sup> dose▶			2 <sup>nd</sup> dose			
Hepatitis A (HepA)					See Notes		2-dose series, See Notes	, See Notes					
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)											10	1 dose	
Human papillomavirus (HPV)											Sğ	See Notes	
Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)							See Notes				1 <sup>st</sup> (	1st dose	2 <sup>nd</sup> dose
Meningococcal B (MenB-4C, MenB-FHbp)												Š	See Notes
Respiratory syncytial virus vaccine (RSV [Abrysvo])												Season during pr	Seasonal administration during pregnancy, See Notes
Dengue (DEN4CYD; 9-16 yrs)											de de	Seropositive in endemic dengue areas (See Notes)	i endemic See Notes)
Мрох													
Range of recommended ages for all children	Range of r for catch-t	Range of recommended ages for catch-up vaccination	d ages n	Rang	Range of recommended ages for certain high-risk groups	led ages roups	Recommended vaccination can begin in this age group	ended vaccina in this age gr		ecommended n shared clinic	Recommended vaccination based on shared clinical decision-making	sed ting	No recommendation/ not applicable

For access to the Notes, Appendix, and Addendum, visit: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-indications.html#addendum-child

escents Who Start Late or Who Are More	
Recommended Catch-up Immunization Schedule for Children and Adolescent	than 1 Month Behind, United States, 2024
C older	

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed

Vaccine	Minimum Age for		Cinitaten aye 4 monuis unougu o years Minimum Interval Between Dases		
	Dose 1	Dose 1 to Dose 2		Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B	Birth	4 weeks	<b>8 weeks and at least 16 weeks after first dose</b> minimum age for the final dose is 24 weeks		
Rotavirus	6 weeks Maximum age for first dose is 14 weeks, 6 days.	4 weeks	<b>4 weeks</b> maximum age for final dose is 8 months, 0 days		
Diphtheria, tetanus, and acellular pertussis	6 weeks	4 weeks	4 weeks	6 months	<b>6 months</b> A fifth dose is not necessary if the fourth dose was administered at age 4 years or adder <i>and</i> at least 6 months after dose 3
Haemophilus influenzae type b	6 weeks	No further doses needed if first dose was administered at age 15 months or older. <b>4 weeks</b> <b>4 weeks</b> <b>4 weeks</b> <b>4 weeks</b> was administered before the 1 <sup>2</sup> birthday. <b>8 weeks (as final dose)</b> if first dose was administered at age if first dose was administered at age	No further doses needed if previous dose was administered at age 15 months or older if neurous dose was administered at age 15 months or older if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRPT (ActHub', Pentacee, Hiberke), Vaxeles" or unknown at least 1 previous dose was PRPT (ActHub', Pentacee, Hiberke), Vaxeles" or unknown at least 1 previous dose was PRPT (ActHub', Pentacee, Hiberke), Vaxeles" or unknown at least 1 previous dose was PRPT (ActHub', Pentacee, Hiberke), Vaxeles" or unknown fi current age is younger than 12 months and first dose was administered before the 1* birthday and second fi current age is 12 through 59 months and first dose was administered before the 1* birthday and second fiber dose was administered before the 1st birthday	B weeks (as final dose) This dose only necessary for children age 12 through 9 months who received 3 doses before the 1 <sup>st</sup> birthday.	
Pneumococcal conjugate	6 weeks	No further doses needed for healthy children if first dose was administered at age 24 months or older 4 weeks if first dose was administered before the 1 <sup>st</sup> birthday 8 weeks (as final dose for healthy first dose was administered at the 1 <sup>st</sup> birthday or after	No further doses needed for healthy children if previous dose was administered at age 24 months or older <b>4 weeks</b> . <i>A weeks</i> if a thread of the neutron and previous dose was administered at months old<br if current age is younger than 12 months <i>and</i> previous dose was administered before old <b>8 weeks (as final dose for healthy children)</b> if previous dose was administered between 7–11 months (wait until at least 12 months old), <b>OR</b> if previous dose was administered between 7–11 months (wait until at least 12 months old), <b>OR</b> if current age is 12 months or older <b>and</b> at least 1 dose was administered before age 12 months	B weeks (as final dose) This dose is only necessary for children age 12 through 59 months regardless of fisk age 60 through 71 months with any fisk, who neceived 3 doses before age 12 months.	
Inactivated poliovirus	6 weeks	4 weeks	<b>4 weeks</b> if currents las final dose) if current age is 4 years or older	6 months (minimum age 4 years for final dose)	
Measles, mumps, rubella Varicella	12 months 12 months	4 weeks 3 months			
Hepatitis A	12 months	6 months			
Meningococcal ACWY	2 months MenACWY-CRM 2 years MenACWY-TT	8 weeks		See Notes	
Meningococcal ACWY	Not applicable (N/A)	8 weeks	Children and adolescents age 7 through 18 years		
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis	7 years	4 weeks	<b>4 weeks</b> if first does of DTaP/DT was administered before the 1 <sup>st</sup> birthday firfirst dose of DTaP/DT or Tdap/Jd was administered at or after the 1 <sup>st</sup> birthday	<b>6 months</b> if first dose of DTaP/DT was administered before the 1 <sup>±</sup> birthday	
Human papillomavirus	9 years	Routine dosing intervals are recommended.			
Hepatitis A	N/A	6 months			
Hepatitis B	N/A	4 weeks	8 weeks and at least 16 weeks after first dose		
Inactivated poliovirus	NA	4 weeks	<b>6 months</b> A fourth dose is not necessary if the third dose was administered at age 4 years or older <b>and</b> at least 6 months after the previous dose.	A fourth dose of IPV is indicated if all previous doses were administered at <4 years <b>OR</b> if the third dose was administered <6 months after the second dose.	
Measles, mumps, rubella	N/A	4 weeks			
Varicella	N/A	<b>3 months</b> if younger than age 13 years. <b>4 weeks</b> if age 13 years or older			
Dengue	9 years	6 months	6 months		

For access to the Notes, Appendix, and Addendum, visit: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-indications.html#addendum-child

Table 3		d Child and Adol	escent Imm	unization Sch	edule by M	ledical Indication,	Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024	
Always use this columns. See No	Always use this table in conjunction with Table 1 and columns. See Notes for medical conditions not listed.	able 1 and the Notes that f not listed.	ollow. Medical co	nditions are often not	mutually exclusi	ive. If multiple conditions ar	Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions are often not mutually exclusive. If multiple conditions are present, refer to guidance in all relevant columns. See Notes for medical conditions not listed.	all relevant
Vaccine and other immunizing agents	Pregnancy	Immunocompromised (excluding HIV infection)	HIV infection CD4 percentage and count <sup>4</sup> <15% or 215% and <200mm	04 unt <sup>a</sup> CSF leak or and cochlear mm implant	Asplenia or persistent complement component deficiencies	Heart disease or chronic lung disease	Kidney failure, End stage renal disease or on Dialysis disease	r Diabetes
RSV-mAb (nirsevimab)		2nd RSV season		1 dose depending on maternal RSV vaccination status, See Notes	maternal See Notes	2nd RSV season for chronic lung disease (See Notes)	1 dose depending on maternal RSV vaccination status, See Notes	maternal , See Notes
Hepatitis B								
Rotavirus		SCID <sup>b</sup>						
DTaP/Tdap	DTaP Tdap: 1 dose each pregnancy							
Чін		HSCT: 3 doses	See Notes		See Notes			
Pneumococcal								
IPV								
COVID-19		See Notes	otes					
IIV4								
LAIV4						Asthma, wheezing: 2–4 years <sup>c</sup>		
MMR	*							
VAR	*							
Hepatitis A								
Л	*	3 dose series	eries. See Notes					
MenACWY								
MenB								
RSV (Abrysvo)	Seasonal administration, See Notes							
Dengue								
Mpox	See Notes							
Recommended fo eligible children w documentation of vaccination series	rall age- ho lack a complete	Not recommended for all children, but is recommended for some children based on increased risk for or severe outcomes from disease		Recommended for all age-eligible children, and additional doses may be necessary based on medical condition or other indications. See Notes.	ole nay be ndition	Preceution: Might be indicated if benefit of protection outweighs risk of adverse reaction	Contraindicated or not recommended *Vaccinate after pregnancy, if indicated	No Guidance/ Not Applicable
<ul> <li>For additional infor "Altered Immunoco www.cdc.gov/vacci</li> </ul>	<ul> <li>For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, "Altered Immunocompetence," at www.cdc.gov/vaccines.hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (footnote J) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.</li> </ul>	eters and use of live vaccines, see the hcp/acip-recs/general-recs/immunocc ndications.html.	General Best Practice Guic ompetence.html and Table	delines for Immunization, 2 4-1 (footnote J) at	b. Sevel	b. Severe Combined Immunodeficiency	<ul> <li>LAIV4 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months</li> </ul>	ildren 2–4 years of age with the preceding 12 months

For access to the Notes, Appendix, and Addendum, visit: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-indications.html#addendum-child